Limitations of metabolic activation systems used with in vitro tests for carcinogens.
Important differences between the metabolic activation of 7,12-dimethylbenz[a]anthracene in intact cellular systems and in liver homogenates suggest that the use of homogenates in conjunction with short-term assays for carcinogens could yield misleading results.
D015127:9,10-Dimethyl-1,2-benzanthracene / Q000378:metabolism*; D000818:Animals; D001551:Benz(a)Anthracenes / Q000378:metabolism*; D002273:Carcinogens / Q000378:metabolism*; D002478:Cells, Cultured; D004247:DNA / Q000378:metabolism; D003853:Deoxyribonucleosides; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006801:Humans; D008099:Liver / Q000378:metabolism*; D051379:Mice; D008862:Microsomes, Liver / Q000378:metabolism; D051381:Rats; D012867:Skin / Q000378:metabolism
D001551:Benz(a)Anthracenes; D002273:Carcinogens; D003853:Deoxyribonucleosides; D015127:9,10-Dimethyl-1,2-benzanthracene; D004247:DNA